CALA News and Press, Calithera Biosciences Inc. From 11/01/21

Calithera Biosciences (NASDAQ:CALA) has added ~4.7% in the pre-market after the company reported interim Phase 1b data from a dose-escalation trial designed to evaluate CB-280 in adults with cystic fibrosis (CF). Data were generated from the first 24 subjects (18 treated with C...

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects -- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride -- Early positive trend seen in FEV1, a safety endpoint SOUTH SAN FRANCIS...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company’s investigational arginase inhibitor for the treatment of cy...

Gainers: Viracta Therapeutics (NASDAQ:VIRX) +5%. Angi (NASDAQ:ANGI) +4%. Calithera Biosciences CALA +3%. Progenity (NASDAQ:PROG) +2%. IVERIC bio (NASDAQ:ISEE) +2%. Losers: TaskUs TASK -8%. DLocal Limited (NASDAQ:DLO) -7%. EverQuote EVER -6%. TORM plc (NASDAQ:TRMD) -4%. Lim...

-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company’s precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022 -- -- Calithera to host webcast and conference call today ...

Energy stocks could be attractive but beware of the macro-economic shifts that may affect the performance. Diversify your portfolio with a mix of sectors. Some strategies can be volatile so know yourself first to manage your emotions. For further details see: The Best Of...

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseas...

Calithera Biosciences, Inc. (CALA) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Stephanie Wong – Chief Financial Officer Susan Molineaux – Founder, President and Chief Executive Officer Keith Orford – Chief Medical Officer Conference Cal...

The following slide deck was published by Calithera Biosciences, Inc. in conjunction with this event. For further details see: Calithera Biosciences (CALA) releases investors presentation